Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.44 |
| ▸ | HTR7 | P34969 | 2/20 | 0.44 |
| ▸ | KDM1A | O60341 | 9/20 | 0.43 |
| ▸ | MAOA | P21397 | 6/20 | 0.43 |
| ▸ | ACLY | P53396 | 1/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4173661 | 0.88 | PDK1 (0.40) | ACLYPDK1 | |
| SCHEMBL4184547 | 0.82 | DRD4 (0.41) | PDK1 | |
| SCHEMBL3162711 | 0.82 | SCN9A (0.48) | — | |
| SCHEMBL4176042 | 0.77 | ALDH1A1 (0.47) | — | |
| SCHEMBL4178403 | 0.76 | TRPC3 (0.41) | KDM1A | |
| SCHEMBL4175075 | 0.75 | GAA (0.43) | — | |
| SCHEMBL3163505 | 0.74 | ALDH1A1 (0.43) | HTR1AHTR7KDM1AMAOA | |
| SCHEMBL4173760 | 0.73 | HCRTR1 (0.46) | — | |
| SCHEMBL4172610 | 0.72 | SCD5 (0.41) | KDM1A | |
| SCHEMBL4178167 | 0.72 | TRPC3 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8357711-B2 | Heterocyclic sulfonamides as inhibitors of ion channels | PFIZER LIMITED (GB) | 2013-01-22 | — | — | US | disclosed |
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (US) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | TRPV1, TRPV5, TRPA1 | HTR1A 1665/4885HTR7 1667/4885KDM1A 2129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.